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We investigated the effect of antiretroviral therapy on vascular activation in 41 human im-
munodeficiency (HIV)– infected patients receiving a regimen that included either at least 1 pro-
tease inhibitor (PI; n ¼ 21) or a nonnucleoside reverse-transcriptase inhibitor (NNRTI; n ¼ 20).
A control group of 21 healthy subjects was included for comparison. Levels of endothelial markers
(soluble vascular cell adhesion molecule [sVCAM]–1, soluble intercellular adhesion molecule–1, and
von Willebrand factor) were higher in HIV-infected persons before treatment than in control subjects
and decreased significantly after 5–13 months of treatment. Levels of sVCAM-1 and von Willebrand
factor correlated significantly with initial virus load. D-dimer concentrations also decreased sig-
nificantly after initiation of treatment. PI- and NNRTI-containing regimens had similar effects.
Therapy did not reduce levels of the soluble platelet (sP) activation markers sP-selectin and
CD40 ligand. The inhibition of markers of vascular activation may counterbalance sequelae of
therapy-induced dyslipidemia and potentially prevent development of atherosclerosis in HIV-
infected patients.
Since highly active antiretroviral therapy (HAART) was in-
troduced into clinical practice in 1995–1996, the morbidity and
mortality associated with human immunodeficiency virus (HIV)
infection has drastically decreased [1–3]. However, protease
inhibitors (PIs) cause long-term side effects, such as dyslipidemia
and, in particular, hypercholesterolemia, which is known to be an
important risk factor for cardiovascular disease [4, 5]. On the
other hand, infectious agents themselves (e.g., viruses or bacteria)
may play an important role in the etiology of the atherosclerosis,
thrombosis, and intimal thickening that occur after arterial injury
[6]. Possible mechanisms involve replication of a pathogen
within human endothelial cells and expression of endothelial
cell markers such as vascular cell adhesion molecule (VCAM)–
1 and intercellular adhesion molecule (ICAM)–1 [7, 8].
Various biological markers of endothelial dysfunction, such
as VCAM-1, ICAM-1, von Willebrand factor, and thrombomod-
ulin, have been described [9]. These markers indicate chronic
endothelial activation and subsequent dysfunction of the endo-
thelium in atherosclerosis. Marked increases in circulating levels
of adhesion molecules were observed in patients with hyperlip-
idemia, hypertension, diabetes mellitus, oxidative stress, changes
in hormone metabolism, and a history of cigarette smoking [10].
Hence, measuring the levels of these molecules in blood may
identify early vascular changes. In earlier studies, we and others
[11–14] found that levels of biological markers of endothelial or
platelet activation are increased in patients with arterial disease
and are associated with progression of atherosclerosis. Endothelial
activation may promote inflammatory reactions and thereby trigger
activation of coagulation mechanisms and induction of a hyper-
coagulable state [10]. This process can be monitored by mea-
surement of coagulation markers. The thrombin–antithrombin III
complex is a marker of intravital thrombin generation. Thrombin
and antithrombin III have very short half-lives (5–7 min) and
are produced whenever the coagulation cascade is sufficiently
activated. D-dimers are fibrin-degradation products, and levels
of D-dimers are elevated whenever cross-linked fibrin is pro-
duced as a result of coagulation activation followed by second-
ary fibrinolysis. Whenever thrombin is generated or endothelial
cells are stimulated, platelets may be activated. Activated platelets,
in turn, can stimulate endothelial cells and induce up-regulation
of various cell adhesion molecules [15].
HIV infection may cause coagulation disorders, most fre-
quently HIV-associated thrombocytopenia [16, 17], but it may
also induce production of antiphospholipid antibodies [18] or
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cause other abnormalities associated with a prothrombotic state
[19]. Endothelial dysfunction or damage, hypercoagulability,
hypertriglyceridemia, and abnormal coronary artery pathology
have all been associated with HIV infection [16, 20, 21]. Levels
of soluble endothelial activation markers (sVCAM-1, sICAM-1,
and von Willebrand factor) are elevated in HIV-infected patients,
and this elevation may be associated with a hypercoagulable state
[22]. Circulating activated platelets also have been found in the
plasma of HIV-infected patients [23] and add to a hypercoagu-
lable state. The degree of hypercoagulability may be propor-
tional to the virus load [22], and elevated levels of sICAM-1
have been associated with disease progression [24]. Reversal
of vascular activation after initiation of antiviral therapy has been
investigated and was demonstrated only for von Willebrand factor
and platelet activation [22, 23]. To assess vascular activation in
patients with HIV infection, we investigated changes in levels of
various endothelial, coagulation, and platelet activation markers.
These were investigated before and after initiation of HAART
(after virus load had decreased substantially, to,400 copies/mL)
in 2 groups of patients receiving 2 different antiretroviral regi-
mens and were compared with levels in healthy control subjects.
Patients and Methods
Patients and control subjects. We selected our patients from
the group of adult patients (age, .16 years) participating in the
Swiss HIV Cohort Study (SHCS) in Basel and Zurich who were
about to start a therapeutic regimen that included either at least 1 PI
(n ¼ 21) or a nonnucleoside reverse-transcriptase inhibitor (NNRTI;
n ¼ 20). Of 115 adult patients who were about to begin receiving
HAART, we excluded 41 who changed therapy before blood sam-
ples were obtained, 4 who were known to be nonadherent to the
therapeutic regimen, and 29 who did not respond well to therapy
(a good response was defined as a virus load ,400 copies/mL).
Within the SHCS, patients are followed up at 6-month intervals
(^1 month). We obtained blood samples at the first follow-up ap-
pointment, 6 months (^1 month) after initiation of HAART, or,
for patients who missed the 6-month consultation or had a virus
load >400 copies/mL at 6 months, at the 12-month follow-up ap-
pointment. The earliest follow-up appointment was at month 5, and
the latest was at month 13. Hence, all patients had information
from 1 follow-up appointment. Age, sex, HIV disease stage (ac-
cording to the Centers for Disease Control and Prevention classifi-
cation [25]), and CD4 cell count were not used as inclusion or ex-
clusion criteria. The mean age in our group of patients was higher
than that in the SHCS group overall (41 vs. 36 years) [26]. The pro-
portion of women was very similar (nonsignificant difference).
With regard to pretherapy parameters, our group had a lower mean
virus load (4.3 vs. 5.01 log10 copies/mL) and a higher mean CD4
cell count (245 vs. 181 cells/mL). Patients who had primary HIV in-
fection or ongoing opportunistic infections were excluded, because
these diseases can interfere with hemostasis. We excluded patients
whose medical history raised suspicion of hereditary coagulation
disorders, such as hemophilia or hereditary thrombophilia. Clinical
information, including age, sex, HIV disease stage, virus load,
CD4 cell count, and platelet count before initiation of therapy
and, thereafter, at follow-up were prospectively collected by cohort
questionnaires and obtained from review of medical files. Twenty-
one healthy HIV-negative blood donors made up the control group.
Blood sampling. Stored plasma samples from HIV-infected
patients were obtained before and at least 5 months after initiation
of HAART. Blood was drawn in 0.11 M sodium citrate (9/1, vol/
vol; used as an anticoagulant) in a Vacutainer CPT system (Becton
Dickinson). After a 2-step centrifugation, plasma was stored at
280C for further use. Specimens from control subjects were ob-
tained and processed in the same manner as specimens from
HIV-infected patients but were only frozen for a few weeks. Re-
cently published data about the stability of the parameters we tested
indicate that coagulation proteins remain stable for at least 18–24
months when stored in frozen plasma at 274C [27]. If a degra-
dation of coagulation proteins were to occur during a longer period
of freezing, it would result in lower levels of markers in samples
from HIV-infected patients but not in samples from control sub-
jects and therefore would strengthen, rather than weaken, our
results.
Laboratory tests. CD4 lymphocyte counts were analyzed by
flow cytometry. For HIV quantification, plasma samples were pro-
cessed according to the published protocols of the Roche HIV-1
Monitor test kit (Roche Diagnostics), with a modification of the
ultrasensitive assay [28].
Levels of biological endothelial activation markers (sVCAM-1,
sICAM-1, von Willebrand factor, and thrombomodulin) were mea-
sured by ELISA (R&D Systems Europe and Diagnostica Stago).
Levels of coagulation activation markers (D-dimers and thrombin–
antithrombin III complex) were also assayed by ELISA (Roche
Diagnostics and Behring Diagnostics). Platelet activation was de-
termined by measurement of soluble platelet (sP) activation mar-
kers (sP-selectin and soluble CD40 ligand), using ELISA (R&D
Systems Europe and Bender Medical Systems).
Statistical analysis. Nonparametric tests were used for statisti-
cal comparison, because some parameters did not show a normal
distribution. Two-group comparisons were done with the Mann-
Whitney U test and the Bonferroni correction for multiple testing
and were confirmed using a 1-way analysis of variance (Scheffe´
test for post hoc multiple comparisons). Paired comparisons were
made with the Wilcoxon rank sum test. Bivariate correlations were
calculated with the Spearman rank correlation. P < :05 was con-
sidered to be significant.
Results
Demographic and laboratory data for case patients and control
subjects are given in table 1. Of 41 case patients, 21 received anti-
retroviral therapy that included 2 nucleoside reverse-transcriptase
inhibitors (NRTIs) and 1 or 2 PIs, and 20 received therapy that
included 2 NRTIs and 1 NNRTI. According to the eligibility
criteria for this investigation, all patients had an HIV load
,400 copies/mL of plasma after initiation of HAART. This
was the case after a mean duration of 9.7 months of antiretro-
viral therapy (5–13 months). Twenty-three patients (56%) had
a virus load,50 copies/mL of plasma at the first follow-up ap-
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pointment. During the study period, the virus load dropped by a
mean ^ SD of 2:9 ^ 1:41 log10 copies/mL (range, 4:3 ^ 1:1 to
1:4 ^ 0:8 log10 copies/mL). Simultaneously, median CD4 cell
counts increased from 210 cells/mL before to 482 cells/mL after
initiation of therapy (table 1). Patients treated with an NNRTI
had smaller baseline and follow-up virus loads. As is shown
in table 1, the decrease in virus load in the 2 treatment groups
was almost identical. Disease characteristics in the 2 treatment
groups were also similar. As expected, all control subjects had
negative results of testing for hepatitis C virus (HCV), whereas
11 (27%) of the case patients were HCV positive.
Endothelial activation. Levels of sVCAM-1, sICAM-1, and
von Willebrand factor were significantly higher in HIV-infected
patients before initiation of antiretroviral treatment than in healthy
control subjects (P , :01). Levels of sVCAM-1, sICAM-1, and
von Willebrand factor, but not of thrombomodulin, decreased
significantly after 5 months of treatment (figure 1), regardless
of whether treatment included PIs or an NNRTI (table 2). The
results of treatment with PIs were very similar to the results of
treatment with an NNRTI, as is shown in figure 1. In addition,
levels of sVCAM-1 correlated significantly with levels of both
sICAM-1 (r ¼ 0:66; P , :001) and von Willebrand factor
(r ¼ 0:59; P , :001), and levels of sICAM-1 correlated with
levels of von Willebrand factor (r ¼ 0:49; P ¼ :001). These
correlations were significant before and after initiation of anti-
retroviral treatment. To test whether initial virus load influenced
levels of endothelial markers, we investigated the association of
baseline virus load with the markers examined in the study.
Levels of sVCAM-1 (r ¼ 0:49; P , :001) and von Willebrand
factor (r ¼ 0:34; P , :03), but not of sICAM-1, correlated sig-
nificantly with virus load. These results demonstrate that marked
endothelial activation was reduced during therapy.
Coagulation activation. To evaluate whether a procoagu-
lant state existed in our patients, we measured levels of markers
of coagulation activation such as thrombin–antithrombin III
complexes and D-dimers before and after initiation of HAART.
Levels of D-dimers decreased significantly in both treatment
groups (figure 1 and table 2) after initiation of treatment. Levels
of thrombin–antithrombin III complex did not increase or de-
crease significantly during therapy (table 2). Interestingly, levels
of D-dimers correlated significantly with levels of von Willebrand
factor (r ¼ 0:38; P , :02), thrombomodulin (r ¼ 0:52; P ,
:01), and sVCAM-1 (r ¼ 0:32; P , :05) before initiation of treat-
ment. After treatment with PIs or NNRTIs, the correlations
between levels of von Willebrand factor and sVCAM-1 dimin-
ished. Levels of D-dimers also correlated highly with the virus
load (r ¼ 0:51; P , :001). In summary, these results demon-
strate that coagulation markers were activated, but to a lesser
degree than were endothelial markers, by HIV infection. Therapy
had a less marked but still obvious effect on coagulation markers.
Platelet activation. To examine whether production of plate-
lets was stimulated by treatment with PIs or NNRTIs, we mea-
sured soluble markers of platelet activation, such as soluble
CD40 ligand and sP-selectin. We found that platelet activation
Table 1. Demographic characteristics and laboratory results for human immunodeficiency virus (HIV)–infected patients
involved in a study of the effects of highly active antiretroviral therapy (HAART) on vascular activation.
Characteristic
All patients
(n = 41)
Patients
receiving PIs
(n = 21)
Patients
receiving NNRTIs
(n = 20)
Control subjects
(n = 21)
Age, mean years (^SD) 41 (11) 40 (11) 41 (11) 46 (14)a
Male sex, no. (%) 31 (76) 19 (90) 12 (60) 16 (76)
HIV disease stage,b no. (%)
A 18 (44) 7 (33) 11 (55)
B 16 (39) 10 (48) 6 (30)
C 7 (17) 4 (19) 3 (15)
Antiviral therapy, no.
2 NRTIs, ritonavir, and saquinavir 15 15
2 NRTIs and ritonavir 2 2
2 NRTIs and indinavir 4 4
2 NRTIs and efavirenz 16 16
2 NRTIs and nevirapine 4 4
Length of treatment, mean months (^SD) 9.7 (2.5) 9.6 (2.5) 9.9 (2.6)
Virus load, mean log10 copies/mL (^SD)
At baseline 4.3 (1.1) 4.7 (0.9) 3.9 (1.3)
After initiation of HAARTc 1.4 (0.8) 1.8 (0.5) 0.9 (0.8)
CD4 T cell count, median cells/mL (range)
At baseline 210 (19–640) 192 (19–640) 315 (80–582)
After initiation of HAART 482 (53–977) 411 (53–972) 500 (79–977)
NOTE. PI, protease inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor.
a Nonsignificant statistical difference (Mann-Whitney U test).
b HIV disease stages are from the Centers for Disease Control and Prevention classification [25].
c Virus load was ,400 copies/mL in all patients; virus load was ,50 copies/mL in 23 patients.
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markers were significantly higher in HIV-infected patients than
in control subjects but did not decrease after initiation of
therapy (table 2). The mean platelet count ^ SD in control sub-
jects was not significantly different from that in HIV-infected
patients (½202 ^ 89 £ 109 vs. ½206 ^ 32 £ 109 platelets/L). Plas-
ma levels of soluble CD40 ligand correlated significantly with
levels of sP-selectin (r ¼ 0:93; P , :001). Levels of sP-selectin
also correlated well with levels of thrombomodulin (r ¼ 0:40;
P , :02)before initiationof treatment, a correlation that dimin-
ished after initiation of treatment with PIs or NNRTIs. In sum-
mary, levels of platelet activation markers were significantly
higher in HIV-infected patients than in healthy control subjects
and did not decrease in response to therapy.
Discussion
In this study, we demonstrated that HIV infection with ongoing
viral replication leads to a significant elevation of endothelial,
platelet, and, to a lesser extent, coagulation activation markers.
We also showed that therapy substantially decreases but does
not completely normalize the endothelial activation state.
Levels of endothelial activation markers are elevated in HIV-
infected patients and are sometimes associated with a hyperco-
agulable state [22]. Activated endothelial cells promote platelet
activation, inflammatory reactions, and progression of athero-
sclerosis [12]. In combination with other humoral factors, these
effects can lead to a prethrombotic state. Indeed, a predisposition
to thrombosis has been described in AIDS patients and was attrib-
uted to changes in various hemostatic balances [19]. In our
patients, levels of biological endothelial markers (sVCAM-1,
sICAM-1, and von Willebrand factor) were high before treat-
ment; they decreased significantly after initiation of treatment
but were still higher than levels in control subjects. This might be
due to persistence of viral replication; concomitant infections,
such as hepatitis C; or differences in smoking history. Interest-
ingly, levels of sVCAM-1 and von Willebrand factor correlated
significantly with levels of D-dimers, which implies that an
association exists between endothelial stimulation and acti-
vation of the coagulation cascade. This correlation diminished
after treatment, probably because levels of endothelial acti-
vation markers decreased.
The levels of markers of platelet activation (soluble CD40
ligand and sP-selectin) were high among HIV-infected patients
Figure 1. Plasma levels of soluble vascular cell adhesion molecule (sVCAM)–1, soluble intercellular adhesion molecule (sICAM)–1, von
Willebrand factor, and D-dimers in human immunodeficiency virus (HIV)–infected patients who received treatment with protease inhibitors
(PIs; n ¼ 21) or a nonnucleoside reverse-transcriptase inhibitor (NNRTI; n ¼ 20), before and after initiation of treatment, compared with levels
in healthy, HIV-negative control subjects (n ¼ 21).
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with platelet counts comparable to those of control subjects.
Both markers normally reside inside the platelet and are ex-
pressed on the surface only after activation and release. CD40
ligand can also be found on macrophages or activated T cells.
Induction of tissue factor expression on macrophages [29] or
endothelial cells [30] by the receptor CD40 and its ligand has
been described. In HIV-infected patients, binding of CD40 li-
gand to its receptors on CD4 cells or endothelial cells may
lead to an increase in the inflammatory reaction, up-regulation
of cell adhesion molecules, and, potentially, a hypercoagulant ef-
fect [15, 30]. In our study, 22% of the case patients but none of
the control subjects presented with thrombocytopenia (platelet
count,150 £ 109 platelets/L). If platelet counts had been high-
er, levels of activation might have been even higher, strength-
ening our comparison of levels of platelet activation in HIV-in-
fected patients with levels in control subjects. In our case
patients, levels of increased soluble CD40 ligand correlated
strongly with levels of sP-selectin, which indicates that these
markers have in common either platelet origin or an event caus-
ing stimulation of platelets and T cells in parallel. CD40 ligand
is expressed on activated T cells, macrophages, mast cells, and
basophils, as well as on the platelet surface after platelet acti-
vation [15, 29, 30]. CD40 ligand plays an important role in
HIV disease progression. CD40 ligand is expressed on acti-
vated T cells and may contribute to the control of viral replica-
tion at the initial stages of HIV infection by stimulating the ex-
pression of chemokines that have an anti-HIV effect [31]. On
the other hand, CD40 ligand activates dendritic cells or macro-
phages later in the progression of HIV disease, thereby stimu-
lating activity of helper T cells and replication of HIV [31].
Our resultsdemonstrate thatendothelial stimulationmayresult
in activation of coagulation and fibrinolysis in HIV-infected
patients. Levels of sVCAM-1 correlated well with levels of D-
dimers and von Willebrand factor. In addition, levels of sVCAM-
1, D-dimers, and von Willebrand factor correlated well with the
virus load before initiation of treatment in our study, indicating
that an association exists between the stimulation of endothelium
and coagulation mechanisms and the effects of HIV infection.
Promotion of bleeding tendency in HIV-infected hemophiliac,
as well as nonhemophiliac, patients by PIs has been described
[32]. This effect has been attributed to a reduction in levels of
platelet activation or possible hypofibrinolysis [23]. One might
speculate that fast reversion of endothelial activation and
elevation of cholesterol levels lead to endothelial destabilization.
In our study, the results of treatment with PIs and NRTIs were
consistent with the results of treatment with an NNRTI and
NRTIs. This may demonstrate that reversion of endothelial acti-
vation is mediated via control of viral replication and not via
mechanisms associated with drug class. In addition, the decrease
of virus load was almost identical in the 2 treatment groups
(table 1). An alternative hypothesis would be that the effects
of therapy are mediated by the NRTIs, which were part of both
regimens.
Our study was not designed to define differences between
the results of treatment with PIs and the results of treatment
with NNRTIs; its primary goal was to assess whether any dif-
ference is seen in levels of endothelial, coagulation, and plate-
let activation markers in HIV-infected patients before and after
initiation of HAART. However, results in patients treated with
PIs and patients treated with NNRTIs show the same trends.
Whether the effects of such treatment reduce the risk of clinically
relevant atherosclerosis, as has been demonstrated in pilot stud-
ies involving patients treated with anti-Chlamydia antibiotics
[33], remains to be proven.
Are the changes found in this study in endothelial, coagu-
lation, and platelet activation biologically relevant? Several
studies confirm that elevated plasma levels of endothelial mark-
ers, such as sVCAM-1 and sICAM-1, may serve as molecular
Table 2. Levels of endothelial, coagulation, and platelet activation markers in human immunodeficiency virus (HIV)–infected patients receiv-
ing protease inhibitors (PIs) or nonnucleoside reverse-transcriptase inhibitors (NNRTIs), compared with levels in HIV-negative control subjects.
Activation marker
Patients receiving PIs (n = 21) Patients receiving NNRTIs (n = 20)
Control subjects
(n = 21)
Before initiation
of treatment
After initiation
of treatment
Before initiation
of treatment
After initiation
of treatment
Endothelial, mean (^SD)
sVCAM-1, ng/mL 595 (266)a 381 (98)a,b 790 (442)a 515 (324)a,b 223 (42)
sICAM-1, ng/mL 313 (125)a 267 (86) a,b 444 (218)a 401 (249)a,b 168 (30)
von Willebrand factor, % 120 (45) 99 (39)b 149 (35)a 129 (33)a,b 98 (28)
Thrombomodulin, ng/mL 78 (16)a 77 (14) 46 (16)a 47 (17)a 67 (11)
Coagulation, mean (^SD)
D-dimers, ng/mL 311 (248) 224 (320)b 141 (118) 74 (57)b 153 (68)
Thrombin–antithrombin III complex, g/L 4.9 (7.7) 3.5 (2.6) 5.5 (5.7) 13 (18.3)a 3.2 (0.6)
Platelet, mean (^SD)
sP-selectin, ng/mL 79 (84)a 67 (16) 49 (32) 58 (44) 34 (9)
Soluble CD40 ligand, ng/mL 2.3 (2.3)a 1.9 (0.7)a 2.3 (3.0) 3.1 (3.4)a 0.7 (0.3)
NOTE. sICAM, soluble intercellular adhesion molecule; sP, soluble platelet; sVCAM, soluble vascular cell adhesion molecule.
a Statistically significantly higher than that of the control group (calculated using 1-way analysis of variance, Scheffe´ test, and Bonferroni correction; P , :05).
b Statistically significantly lower than values before initiation of treatment (calculated using paired Wilcoxon rank sum test; P , :01).
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markers for atherosclerosis and are independent risk factors for
the development of coronary heart disease [34, 35]. In addition,
elevated plasma levels of D-dimers are independently associ-
ated with myocardial infarction, and reduction of levels of von
Willebrand factor might protect patients from myocardial in-
farction [36, 37]. The degree of platelet activation found in our
patients may represent a biologically and clinically significant
risk factor for thrombotic events [23, 38]. The degree of eleva-
tion of levels of the investigated factors in HIV-infected patients
is similar to or even greater in magnitude than changes reported
to be a risk factor for cardiovascular disease. One study reports
that patients with incident coronary heart disease or carotid ar-
tery atherosclerosis had mean ICAM-1 levels of 289 ng/mL
and 284 ng/mL, respectively, compared with 244 ng/mL in
healthy control subjects [39]. This is in keeping with the find-
ings of another study, in which the mean ICAM-1 level was
measured at 320 ng/mL in patients with coronary heart disease
and at 275 ng/mL in control subjects [40].
Unlike the authors of other studies, we did not observe a de-
crease in levels of platelet activation markers in patients who
were receiving antiretroviral treatment [23]. This may be due
to the short observation period that we used and the low mean
virus load found in our patients before initiation of antiretroviral
therapy. In our study, cholesterol levels increased after initiation
of antiretroviral therapy in patients who received PIs (data not
shown), which strengthens the interpretation of our results. High-
er cholesterol concentrations are associated with endothelial,
coagulation, and platelet activation [41, 42]. Our patients had
less-pronounced viral activity and higher CD4 cell counts than
other patients in the SHCS [26]. It may be that the differences in
levels before and after initiation of HAART would be even more
pronounced in patients who have more-advanced disease.
Our study may have limitations. For example, differences in
HCV positivity might explain some of the differences seen be-
tween patients and control subjects; infection with pathogens
other than HIV could lead to elevated levels of endothelial and
coagulation markers. However, it can be assumed that antiretroviral
therapy had a negligible impact on activity of HCV. Therefore,
differences seen in levels of markers before and after initiation
of HAART should not be influenced by HCV infection. Smok-
ing history was not assessed, but smoking might have influ-
enced the levels of endothelial and coagulation activation in
patients and control subjects. However, changes in the param-
eters we investigated that occurred after initiation of therapy
would not be influenced by this, because smoking cessation
was probably rare in HIV-infected patients during the follow-
up period.
Several questions remain unanswered (e.g., what is the mo-
lecular mechanism of this effect?). Although our study needs
confirmation from larger trials, our results indicate that anti-
retroviral treatment in HIV-infected patients that is associated
with decreased endothelial and coagulation activation may
reduce inflammation and, thereby, the risk of atherosclerosis.
Whether the observed effects reduce the risk of atherosclerosis
in HIV-infected individuals treated with HAART who present
with associated dyslipidemia remains to be proven. Certainly,
such mechanisms are not sufficient to prevent all atherosclerotic
development; premature lesions of the carotid vessels have been
observed in HIV-infected patients treated with PIs [43]. Never-
theless, the beneficial effects might postpone clinical manifes-
tations of atherosclerosis, such as coronary artery disease or
stroke.
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